Valuation: Makers Laboratories Limited

Market Cap 88Cr 91.75L 80.18L 73.99L 68.2L 1.29Cr 1.31Cr 8.84Cr 3.48Cr 43Cr 3.45Cr 3.37Cr 148.97Cr P/E 2025
10.2x
P/E 2026 33.9x
Enterprise Value 83Cr 85.88L 75.05L 69.26L 63.84L 1.2Cr 1.23Cr 8.28Cr 3.26Cr 41Cr 3.23Cr 3.15Cr 139.45Cr EV / Sales 2025
0.67x
EV / Sales 2026 0.53x
Free-Float
32.66%
Yield 2025 *
-
Yield 2026 -
26/05 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
10/02 Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
07/11 Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
29/25/29 CARE Affirms BBB+ Rating on Makers Laboratories' Long-Term Bank Financing; Outlook Stable MT
08/25/08 Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
08/25/08 Makers Laboratories Returns to Consolidated Profit in Fiscal Q1; Shares Slide MT
26/25/26 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
29/24/29 Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
06/24/06 Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
23/24/23 Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories MT
23/24/23 Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
23/24/23 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
15/24/15 Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024 CI
1 day-0.03%
1 week-1.87%
Current month+2.67%
1 month+1.32%
3 months-2.85%
6 months+22.15%
Current year+26.75%
1 week 148.25
Extreme 148.25
154.6
1 month 140.95
Extreme 140.95
168.5
Current year 112.1
Extreme 112.1
186.7
1 year 109
Extreme 109
186.7
3 years 98.05
Extreme 98.05
230
5 years 94
Extreme 94
238
10 years 23.2
Extreme 23.2
344.8
Manager TitleAgeSince
Chief Executive Officer 51 11/08/2011
Director of Finance/CFO 59 30/10/2017
Compliance Officer - 23/05/2024
Director TitleAgeSince
Director/Board Member 79 29/04/2009
Chairman 77 28/03/2019
Director/Board Member 51 11/08/2011
Change 5-day change 1-year change 3-year change Capi.($)
-0.03%-1.87%+0.23%+32.58% 91.78L
+1.23%+1.82%+15.61%+78.24% 4.82TCr
-0.23%-1.65%+67.15%+109.36% 3.56TCr
+1.61%+1.04%-2.19%+36.44% 1.19TCr
+0.46%+1.56%+18.45%+86.06% 1.18TCr
+0.93%+2.87%+34.92%+137.61% 930.92Cr
+3.37%-0.10%+51.64%-4.77% 701.98Cr
-0.29%+0.34%+16.15%+34.84% 690.82Cr
-.--%+0.14% - - 678.76Cr
+0.18%-2.69%+2.50%+202.37% 655.09Cr
Average +0.72%-0.44%+22.72%+79.19% 1.44TCr
Weighted average by Cap. +0.74%-0.68%+30.22%+86.88%

Financials

2025 2026
Net sales 120.75Cr 1.25Cr 1.1Cr 1.01Cr 93.2L 1.76Cr 1.8Cr 12Cr 4.75Cr 59Cr 4.71Cr 4.61Cr 203.58Cr 140.87Cr 1.46Cr 1.28Cr 1.18Cr 1.09Cr 2.05Cr 2.09Cr 14Cr 5.55Cr 69Cr 5.49Cr 5.37Cr 237.51Cr
Net income 7.49Cr 8L 7L 6L 6L 10.9L 11.14L 74.97L 29.49L 3.67Cr 29.21L 28.57L 13Cr 2.35Cr 2L 2L 2L 2L 3L 3L 23.53L 9L 1.15Cr 9L 9L 3.96Cr
Net Debt 4.82Cr 5L 4L 4L 4L 7L 7L 48.23L 18.97L 2.36Cr 18.79L 18.38L 8.13Cr -5.65Cr -6L -5L -5L -4L -8L -8L -56.55L -22.24L -2.77Cr -22.03L -21.55L -9.53Cr
Logo Makers Laboratories Limited
Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company's segments include Pharmaceutical and Chemical Manufacturing. It has one manufacturing unit in India manufacturing formulations for the Indian market. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimesulide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). It also offers a range of diabetic and hypertensive drugs, including Voglibose, Gli-me range (Glimepiride + Metformin +Pioglitazone), and Hypernorm range (Telmisartan). Its product categories include Inspira - Retail Packs and Experia - Bulk Packs. Its Inspira - Retail Packs include anthelmintics, anti-biotics, anti-emetics and anti-nauseants. Its Experia - Bulk Packs include betamethasone 0.5 mg tablets, chloramphenicol capsules 250 mg and diclofenac 50 mg tablets.
Employees
114
Date Price Change Volume
20/26/20 149.75 -0.03% 10
17/26/17 ₹149.80 -0.07% 805
16/26/16 ₹149.90 +0.44% 3,284
15/26/15 ₹149.25 -2.77% 1,100
14/26/14 ₹153.50 +0.59% 800
  1. Stock Market
  2. Stocks
  3. MAKERSL6 Stock